Article Text

PDF
Treatment of macular degeneration – controversy and hope
  1. S J McGimpsey,
  2. M C Gillies
  1. Save Sight Institute, Sydney Hospital and Sydney Eye Hospital, 8 Maquarie Street, Sydney NSW 2001, Australia
  1. S J McGimpsey, Save Sight Institute, Sydney Hospital and Sydney Eye Hospital, 8 Maquarie Street, Sydney NSW 2001, Australia; stuart.mcgimpsey{at}gmail.com

Statistics from Altmetric.com

Recently two anti-vascular endothelial growth factor inhibitors have been developed which appear to improve vision in age-related macular degeneration (AMD). Ranibizumab has been through a rigorous trial process assessing its efficacy and safety and is expensive, while bevacizumab, which costs a fraction of the price, has not. A recent internet survey suggested a very low rate of systemic side effects with bevacizumab. We report three patients in a series of 126 injections who developed a thromboembolic event soon after treatment. While these events may be unrelated, we suggest there may be gross under-reporting of systemic adverse events by data collected informally.

With an ageing population in the developed world, the prevalance of AMD, a condition that can cause blindness, is on the increase. Over the past …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.